Department of Molecular Medicine

Tim Huang Tim Hui-Ming  HuangPh.D.

Professor and Chair

Profile and Contact Information | Research | Laboratory



Research Program

Dr. Huang has been conducting studies on cancer epigenetics for the last 27 years. He has pioneered the development of high-throughput technologies that are used to investigate molecular interactions between DNA methylation and histone modifications during tumorigenesis. Presently, Dr. Huang and his team members utilize next-generation sequencing approaches to decipher complex epigenetic profiles of various cancer subtypes. These omics approaches are used in combination with statistical and bioinformatic tools to develop biological models of epigenetic regulation of gene expression. In addition to studying epigenetic regulatory mechanisms, Dr. Huang has identified DNA methylation biomarkers that stratify clinicopathological subtypes of solid tumors. These biomarkers will be used to predict treatment outcomes of cancer patients undergoing Phase I clinical trials with combined inhibitors specifically targeting aberrant DNA methylation and oncogenic signaling.


Selected Publications

  1. Horning, A.M., Wang, V.Y., Lin, C.-K., Louie1, A.D., Jadhav, R.R., Lin, C.L., Kirma, N., Liss, M.A., Kumar, A.P., Liu, Z., Wang, Q., Jin, V.X., Chen, C.L. & Huang, T.H. Single-cell RNA-seq reveals a hidden subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response. Cancer Research, 78(4): 853-864 (2018) PMID: 29233929

  2. Hsu, Y.T., Osmulsk, P., Wang, Y., Huang, Y.W., Liu, L., Ruan, J., Jin, V.X., Kirma, N.B., Gaczynska, M.E. and Huang, T.H.-M. “EpCAM-regulated transcription exerts influences on nanomechanical properties of endometrial cancer cells that promote epithelial-to-mesenchymal transition. Cancer Res. 76:6171-6182 (2016). PMID: 27569206.

  3. Hsu PY, Hsu HK, Hsaio TH, Ye Z, Wang E, Profit AL, Jatoi I, Chen Y, Kirma NB, Jin VX, Sharp ZD, Huang TH. Spatiotemporal control of estrogen-responsive transcription in ER α-positive breast cancer cells. Oncogene. 2016; 35(18):2379-89. PMID: 26300005.

  4. Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell. 2013 Aug 12;24(2):197-212.

  5. Hsu YT, Gu F, Huang YW, Liu J, Ruan J, Huang RL, Wang CM, Chen CL, Jadhav RR, Lai HC, Mutch DG, Goodfellow PJ, Thompson IM, Kirma NB, Huang TH. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013 Nov 15;19(22):6272-85.

  6. Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu F, Huang YW, Liyanarachchi S, Deatherage DE, Hsu PY, Taslim C, Ramaswamy B, Shapiro CL, Lin HJ, Cheng AS, Jin VX, and Huang TH: (2011) Epigenetic silencing mediated through activated P13K/AKT signaling in breast cancer. Cancer Res. 71(5): 1752-62.

  7. Hsu PY, Hsu HK, Singer GA, Yan PS, Rodriguez BA, Liu JC, Weng YI, Deatherage DE, Chen Z, Pereira JS, Lopez R, Russo J, Wang Q, Lamartiniere CA, Nephew KP, and Huang TH: (2010) Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res. 20(6): 733-44.

Complete list of published work.